Skip to main content
Top
Published in: Cost Effectiveness and Resource Allocation 1/2018

Open Access 01-12-2018 | Research

Budget impact analysis of the adoption of new hypertension guidelines in Colombia

Authors: Cesar Augusto Guevara-Cuellar, Victoria Eugenia Soto, María Isabel Molina-Echeverry

Published in: Cost Effectiveness and Resource Allocation | Issue 1/2018

Login to get access

Abstract

Background

Hypertension represents a high burden of disease in different healthcare systems. Recent guideline published in 2017 by the American Heart Association and the American College of Cardiology has generated a debate between clinicians and policymakers due to the lowering of diagnosis threshold and the subsequent increase of the prevalence and healthcare costs. No empirical research exists addressing the question about the pressure on healthcare costs generated by new standards. This study aims to quantify the impact on the hypertension diagnosis and treatment costs for healthcare system using the new hypertension guideline.

Methods

We conducted a budget impact analysis from a Colombian healthcare payer’s perspective with a 3-year time horizon (2018–2020), in which we estimated the difference in total medical care costs between previous hypertension cut-off points (140/90 mmHg) and new guideline cut-off points (130/80 mmHg).

Results

Our results show that the impact of the adoption of the new hypertension guideline would represent a decrease close to 22% in total annual high blood pressure costs in Colombia. This reduction is mainly driven by a lower number of cardiovascular complications. It is worth noting that these results should be taken with caution due to local available data.

Conclusions

A high-middle income country such as Colombia should carry out an exhaustive revision of the recommendations of the new hypertension guideline, due to its high probability of saving medical treatment costs for the healthcare system.
Appendix
Available only for authorised users
Literature
2.
go back to reference Stevens B, Verdian L, Pezzullo L, Tomlinson J, Zegenhagen S. The economic burden of hypertension in Latin America. Value Health. 2016;19:647–8. Stevens B, Verdian L, Pezzullo L, Tomlinson J, Zegenhagen S. The economic burden of hypertension in Latin America. Value Health. 2016;19:647–8.
3.
go back to reference Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Pr. Hypertension. American Heart Association, Inc. 2017. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Pr. Hypertension. American Heart Association, Inc. 2017.
4.
go back to reference Wander GS, Ram CVS. Global impact of 2017 American Heart Association/American College of Cardiology hypertension guidelines: a perspective from India. Circulation. 2018;137:549–50.CrossRef Wander GS, Ram CVS. Global impact of 2017 American Heart Association/American College of Cardiology hypertension guidelines: a perspective from India. Circulation. 2018;137:549–50.CrossRef
5.
go back to reference Kario K. Global impact of 2017 American Heart Association/American College of Cardiology hypertension guidelines: a perspective from Japan. Circulation. 2018;137:543–5.CrossRef Kario K. Global impact of 2017 American Heart Association/American College of Cardiology hypertension guidelines: a perspective from Japan. Circulation. 2018;137:543–5.CrossRef
6.
go back to reference Wang J-G, Liu L. Global impact of 2017 American College of Cardiology/American Heart Association hypertension guidelines: a perspective from China. Circulation. 2018;137:546–8.CrossRef Wang J-G, Liu L. Global impact of 2017 American College of Cardiology/American Heart Association hypertension guidelines: a perspective from China. Circulation. 2018;137:546–8.CrossRef
12.
go back to reference Shihab HM, Meoni LA, Chu AY, Wang N-Y, Ford DE, Liang K-Y, et al. Body mass index and risk of incident hypertension over the life course: the Johns Hopkins Precursors Study. Circulation. 2012;126:2983–9.CrossRef Shihab HM, Meoni LA, Chu AY, Wang N-Y, Ford DE, Liang K-Y, et al. Body mass index and risk of incident hypertension over the life course: the Johns Hopkins Precursors Study. Circulation. 2012;126:2983–9.CrossRef
18.
go back to reference Setia S, Subramaniam K, Tay JC, Teo BW. Hypertension and blood pressure variability management practices among physicians in Singapore. Vasc Health Risk Manag. 2017;13:275–85.CrossRef Setia S, Subramaniam K, Tay JC, Teo BW. Hypertension and blood pressure variability management practices among physicians in Singapore. Vasc Health Risk Manag. 2017;13:275–85.CrossRef
20.
go back to reference Machado-Duque ME, Ramírez-Valencia DM, Medina-Morales DA, Machado-Alba JE. Effectiveness and clinical inertia in the management of hypertension in patients in Colombia. J Am Soc Hypertens. 2015;9:878–84.CrossRef Machado-Duque ME, Ramírez-Valencia DM, Medina-Morales DA, Machado-Alba JE. Effectiveness and clinical inertia in the management of hypertension in patients in Colombia. J Am Soc Hypertens. 2015;9:878–84.CrossRef
25.
go back to reference Dasbach EJ, Elbasha EH. Verification of decision-analytic models for health economic evaluations: an overview. Pharmacoeconomics. 2017;35:673–83.CrossRef Dasbach EJ, Elbasha EH. Verification of decision-analytic models for health economic evaluations: an overview. Pharmacoeconomics. 2017;35:673–83.CrossRef
26.
go back to reference Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB, et al. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Value Health. 2012;15:843–50.CrossRef Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB, et al. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Value Health. 2012;15:843–50.CrossRef
27.
go back to reference Ozcan YA. Quantitative methods in health care management: techniques and applications. New York: Wiley; 2009. Ozcan YA. Quantitative methods in health care management: techniques and applications. New York: Wiley; 2009.
29.
go back to reference Nelson MR, McNeil JJ, Peeters A, Reid CM, Krum H. PBS/RPBS cost implications of trends and guideline recommendations in the pharmacological management of hypertension in Australia, 1994–1998. Med J Aust. 2001;174:565–8.PubMed Nelson MR, McNeil JJ, Peeters A, Reid CM, Krum H. PBS/RPBS cost implications of trends and guideline recommendations in the pharmacological management of hypertension in Australia, 1994–1998. Med J Aust. 2001;174:565–8.PubMed
30.
go back to reference Sun P, Chang J, Zhang J, Kahler KH. Evolutionary cost analysis of valsartan initiation among patients with hypertension: a time series approach. J Med Econ. 2012;15:8–18.CrossRef Sun P, Chang J, Zhang J, Kahler KH. Evolutionary cost analysis of valsartan initiation among patients with hypertension: a time series approach. J Med Econ. 2012;15:8–18.CrossRef
31.
go back to reference Volpe M, Machado E. Treatment priorities and current prescribing patterns in hypertension: results of GRASP, an international physician survey. Curr Med Res Opin. 2004;20:1151–60.CrossRef Volpe M, Machado E. Treatment priorities and current prescribing patterns in hypertension: results of GRASP, an international physician survey. Curr Med Res Opin. 2004;20:1151–60.CrossRef
32.
go back to reference Koçkaya G, Wertheimer A. Can we reduce the cost of illness with more compliant patients? An estimation of the effect of 100% compliance with hypertension treatment. J Pharm Pract. 2011;24:345–50.CrossRef Koçkaya G, Wertheimer A. Can we reduce the cost of illness with more compliant patients? An estimation of the effect of 100% compliance with hypertension treatment. J Pharm Pract. 2011;24:345–50.CrossRef
33.
go back to reference Aellig WH. Adverse reactions to antihypertensive therapy. Cardiovasc Drugs Ther. 1998;12:189–96.CrossRef Aellig WH. Adverse reactions to antihypertensive therapy. Cardiovasc Drugs Ther. 1998;12:189–96.CrossRef
34.
go back to reference Burke V, Beilin LJ, Cutt HE, Mansour J, Wilson A, Mori TA. Effects of a lifestyle programme on ambulatory blood pressure and drug dosage in treated hypertensive patients: a randomized controlled trial. J Hypertens. 2005;23:1241–9.CrossRef Burke V, Beilin LJ, Cutt HE, Mansour J, Wilson A, Mori TA. Effects of a lifestyle programme on ambulatory blood pressure and drug dosage in treated hypertensive patients: a randomized controlled trial. J Hypertens. 2005;23:1241–9.CrossRef
36.
go back to reference Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet (London, England). 2014;383:1899–911.CrossRef Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet (London, England). 2014;383:1899–911.CrossRef
38.
go back to reference Palmieri V, Pezzullo S, Lubrano V, Bettella S, Olandese M, Sorrentino C, et al. Home-based telemonitoring of simple vital signs to reduce hospitalization in heart failure patients: real-world data from a community-based hospital. G Ital Cardiol. 2011;12:829–36. Palmieri V, Pezzullo S, Lubrano V, Bettella S, Olandese M, Sorrentino C, et al. Home-based telemonitoring of simple vital signs to reduce hospitalization in heart failure patients: real-world data from a community-based hospital. G Ital Cardiol. 2011;12:829–36.
Metadata
Title
Budget impact analysis of the adoption of new hypertension guidelines in Colombia
Authors
Cesar Augusto Guevara-Cuellar
Victoria Eugenia Soto
María Isabel Molina-Echeverry
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Cost Effectiveness and Resource Allocation / Issue 1/2018
Electronic ISSN: 1478-7547
DOI
https://doi.org/10.1186/s12962-018-0152-5

Other articles of this Issue 1/2018

Cost Effectiveness and Resource Allocation 1/2018 Go to the issue